Avalo Therapeutics, INC Form 4 insider transactions

Avalo Therapeutics, Inc. Director Aaron Kantoff was granted 20,100 stock options with an exercise price of $4.47, vesting on June 17, 2026.

Avalo Therapeutics, Inc. Director Michael Thomas Heffernan was granted 29,500 stock options with an exercise price of $4.47, vesting on the first anniversary of the grant date.

Avalo Therapeutics, Inc. Director June Sherie Almenoff was granted 20,100 stock options with an exercise price of $4.47, vesting fully on the first anniversary of the grant date.

Avalo Therapeutics, Inc. Director Rita Jain was granted 40,200 stock options with an exercise price of $4.47, vesting over three years.

Director Mitchell Chan exercised restricted stock units of Avalo Therapeutics, Inc. on March 28, 2025, converting them into 3,167 shares of common stock.

Director Jonathan Goldman reports the vesting of restricted stock units into common stock of Avalo Therapeutics.

Director Samantha Truex acquired 3,167 shares of Avalo Therapeutics common stock through the vesting of restricted stock units on March 28, 2025.

Director Aaron Kantoff acquired 3,167 shares of Avalo Therapeutics common stock on March 28, 2025, through the vesting of restricted stock units.

Director Gilla Kaplan acquired 3,167 shares of Avalo Therapeutics common stock through the vesting of restricted stock units on March 28, 2025.

Director June Sherie Almenoff exercised restricted stock units of Avalo Therapeutics, Inc. on March 28, 2025, converting them into common stock.

Christopher Ryan Sullivan, CFO of Avalo Therapeutics, reports the acquisition and disposal of common stock and restricted stock units on March 28, 2025.

CEO Neil Garry Arthur of Avalo Therapeutics reports the vesting and conversion of restricted stock units into common stock, along with a disposition of shares to cover tax obligations.

Director Michael Heffernan received stock options for 50,000 shares of Avalo Therapeutics, Inc. (AVTX) on March 25, 2025.

Avalo Therapeutics' Chief Legal Officer, Paul Varki, was granted 100,000 stock options on January 28, 2025.

Avalo Therapeutics' Chief Financial Officer, Christopher Ryan Sullivan, was granted 163,000 stock options on January 28, 2025.

Avalo Therapeutics CEO and Chairman, Garry Arthur Neil, was granted 411,000 stock options on January 28, 2025.

A Form 4 filing reveals that Avalo Therapeutics' Chief Medical Officer, Mittie Doyle, was granted stock options on January 28, 2025.

Jennifer Riley, Chief Strategy Officer of Avalo Therapeutics, received stock options for 150,000 shares on January 1, 2025, according to a Form 4 filing.

Director June Sherie Almenoff has increased her indirect holdings in Avalo Therapeutics through purchases of common stock via Meadowlark Management, LLC.

Director Jonathan Goldman acquired stock options and restricted stock units in Avalo Therapeutics, according to a Form 4 filing.

Director Mitchell Chan acquired stock options and restricted stock units in Avalo Therapeutics, according to a Form 4 filing.

Director June Sherie Almenoff acquired stock options for 24,600 shares and 9,500 restricted stock units in Avalo Therapeutics, Inc.

Director Aaron Kantoff received stock options and restricted stock units from Avalo Therapeutics on August 13, 2024.

Director Samantha Truex acquired stock options and restricted stock units in Avalo Therapeutics, according to a Form 4 filing.

Director Gilla Kaplan of Avalo Therapeutics acquired stock options and restricted stock units on August 13, 2024, according to a Form 4 filing.

Christopher Ryan Sullivan, CFO of Avalo Therapeutics, Inc., received stock options and restricted stock units on August 13, 2024.

Avalo Therapeutics CEO Garry Arthur Neil was granted stock options and restricted stock units on August 13, 2024, according to a Form 4 filing.

A Form 4 filing reveals that Avalo Therapeutics' Chief Medical Officer, Mittie Doyle, was granted stock options on July 15, 2024.

Paul Varki, Chief Legal Officer of Avalo Therapeutics, reports the acquisition of stock options.